UM-SCC-105 Human Squamous Carcinoma Cell Line

Access to UM-SCC-105 Cells is limited solely to those officers, employees and students of PURCHASER′s institution who need access to perform research. PURCHASER may not distribute UM-SCC-105 Cells or derivatives to third parties. PURCHASER shall comply with all applicable laws in its use and handling of the Product and shall keep it under reasonable safe and secure conditions to prevent unauthorized use or access.THIS PRODUCT IS ONLY AVAILABLE FOR SALE TO ACADEMIC INSTITUTIONS OR NOT-FOR-PROFIT ENTITIES FOR USE UNDER THIS LIMITED USE LABEL LICENSE. FOR INFORMATION ON COMMERCIAL LICENSING OF UM-SCC-105 CELLS, INCLUDING LICENSING TO COMMERCIAL ENTITIES, PLEASE CONTACT: licensing@milliporesigma.com.

The HPV18-positive SCC-105 squamous cell carcinoma cell line was derived from the laryngeal tumor of a 51yo never-smoker male and is a suitable in vitro model of H&N carcinoma studies.

HPV-related head and neck cancers are often more responsive with current therapeutic protocols when compared to HPV-negative tumors that are derived from the same anatomical location. This has propagated interest in reducing the intensity levels of treatment. However, even when combining strong therapeutic approaches with chemotherapy, 20-30% of HPV-positive cancers progress and no longer respond to treatment methods. This makes it continually important to understand why certain tumors progress while others appropriately respond to treatment. ​​The UM-SCC-105 cell line is HPV18-positive. This cell line was biopsied from a laryngeal tumor of a 51-year-old never-smoker male individual. It is understood that the cancer progression was driven by E6/E7 viral mechanisms rather than cell cycle mutations typically related to tobacco smoke carcinogenesis, giving this cell line a unique background. Other mechanisms, such as understanding viral integration into the host genome, continue to be an important aspect of understanding HPV-driven cancers. The UM-SCC-105 cell line positively expresses head and neck cancer markers such as ALDH1, CD44, and ABCG2. ALDH1 and CD44 have both been implicated as cancer stem cell (CSC) markers in head and neck cancers. CSCs are often associated with a poor prognosis and are necessary to understanding aggressive tumor behavior that overcomes treatment. ABCG2 is also addressed as a common head and neck squamous cell carcinoma marker. ABCG2 functions as an efflux pump and is associated with anticancer drug resistance. Source: The UM-SCC-105 cell line is derived from a biopsied laryngeal tumor of a 51-year-old “never smoker” male.​References: 1. Front Oncol. (2021); 11: 606010.2. Head Neck (2016); 38(Suppl 1): E459-E467. 3. Head Neck (2017); 39(5): 840-852.4. Exp Ther Med (2011); 2(6): 1151-1157.

UM-SCC-105 cells should be stored in liquid nitrogen until use. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.